NasdaqCM - Nasdaq Real Time Price USD

Edesa Biotech, Inc. (EDSA)

2.3500

-0.0100

(-0.42%)

As of 3:53:12 PM EDT. Market Open.

Edesa Biotech Announces Chief Financial Officer Transition

TORONTO, April 04, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced the appointment of Peter J. Weiler as Chief Financial Officer, effective May 1, 2025. Mr. Weiler will succeed Stephen Lemieux, who will be stepping down from the role effective May 1, 2025, to pursue other professional opportunities. Mr. Weiler brings extensive experience in fin

GlobeNewswire 19 days ago

EDSA
-0.42%
EDSA: Raises $15 Million to Advance EB06…

By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Advancing EB06 for Treating Vitiligo Edesa Biotech, Inc. (NASDAQ:EDSA) is planning for a Phase 2 study of its anti-CXCL10 monoclonal antibody for the treatment of moderate-to-severe non-segmental vitiligo patients. Vitiligo is a disease that causes areas of the skin to lose color, with non-segmental vitiligo being

Zacks Small Cap Research last month

EDSA
-0.42%
US Penny Stocks To Watch In February 2025

As the S&P 500 hovers near record highs and treasury yields drop following retail sales data, investors are keeping a close eye on the broader U.S. market trends. Penny stocks, often associated with smaller or newer companies, remain an intriguing investment area despite their vintage name. These stocks can offer a blend of affordability and growth potential when backed by solid financials, making them worth considering for those seeking opportunities in this unique segment of the market.

Simply Wall St. 2 months ago

EDSA
-0.42%
FRGE

CERS
Edesa Biotech Announces $15.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Financing led by Velan Capital with participation from new and existing healthcare-focused institutional investors and insidersCapital raise to fund Edesa’s CXCL10 antibody program through the end of fiscal 2026 TORONTO, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA) (the “Company” or “Edesa”), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced that it has sold, in a private placement

GlobeNewswire 2 months ago

EDSA
-0.42%
EDSA: IND Expected in 2025 for EB06 for the Treatment of Vitiligo…

By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Advancing EB06 for Treating Vitiligo Edesa Biotech, Inc. (NASDAQ:EDSA) is planning for a Phase 2 study of its anti-CXCL10 monoclonal antibody for the treatment of moderate-to-severe non-segmental vitiligo patients. Vitiligo is a disease that causes areas of the skin to lose color, with non-segmental vitiligo being

Zacks Small Cap Research 2 months ago

EDSA
-0.42%
Edesa Biotech And 2 Other Promising US Penny Stocks For Your Radar

As the Dow Jones Industrial Average experiences a prolonged losing streak and investors closely watch Federal Reserve decisions, market participants are seeking opportunities that might weather such volatility. Penny stocks, though often seen as speculative, can still hold potential when they exhibit strong financial fundamentals. These smaller or newer companies may offer unique value propositions and growth prospects that could appeal to investors looking for under-the-radar opportunities...

Simply Wall St. 4 months ago

SPRU

EDSA
-0.42%
BRNS
Edesa Biotech Reports Fiscal Year 2024 Results

TORONTO, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the fiscal year ended September 30, 2024 and provided an update on its business. During the fiscal year, the company pivoted the in-house development of its anti-TLR4 drug candidate, EB05 (paridiprubart), to a U.S. government-funded study investigating novel

GlobeNewswire 4 months ago

EDSA
-0.42%
Edesa Biotech’s Founder Makes Strategic Investment in the Company

TORONTO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced that the company has entered into a purchase agreement with an entity affiliated with Par Nijhawan, MD, Edesa’s Chief Executive Officer and Founder, to invest up to $5.0 million in the company, including an immediate investment of approximately $1.5 million. The entity will purch

GlobeNewswire 5 months ago

EDSA
-0.42%
Edesa Biotech Announces Upcoming Conference Schedule

TORONTO, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today that Edesa management and business development staff plan to participate in the following upcoming conferences: BIO-Europe, Stockholm, Sweden, November 4-6, 2024Dermatology Drug Development Summit, Boston, Mass., November 12-14, 2024LSX Investival Showcase, London, UK, November 1

GlobeNewswire 5 months ago

EDSA
-0.42%
EDSA: EB05 Selected for BARDA-Funded Study in ARDS…

By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT Business Update EB05 Selected for U.S. Government Funded Study in ARDS In June 2024, Edesa Biotech, Inc. (NASDAQ:EDSA) announced that EB05 (paridiprubart) was selected by the Biomedical Advanced Research and Development Authority (BARDA) for testing in a U.S. government-funded clinical trial to test three novel threat-agnostic

Zacks Small Cap Research 7 months ago

EDSA
-0.42%
BARDA Selects Edesa Biotech's Drug for U.S. Funded Platform Trial in General ARDS

This Phase 2 clinical study will evaluate paridiprubart (EB05) in hospitalized patients with acute respiratory distress syndrome (ARDS) due to a variety of causes. This BARDA-funded project is expected to complement Edesa's ongoing drug development ...

ACCESS Newswire 9 months ago

EDSA
-0.42%
EDSA: Preparing IND for Phase 2 Trial of EB06 in Vitiligo

By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Readying IND for EB06 in Vitiligo Edesa Biotech, Inc. (NASDAQ:EDSA) is planning for a Phase 2 study of its anti-CXCL10 monoclonal antibody for the treatment of moderate-to-severe non-segmental vitiligo patients. Vitiligo is a disease that causes areas of the skin to lose color, with non-segmental vitiligo being

Zacks Small Cap Research 10 months ago

EDSA
-0.42%
Edesa Biotech Reports Fiscal 2nd Quarter 2024 Results

TORONTO, ON / ACCESSWIRE / May 10, 2024 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three ...

ACCESS Newswire 11 months ago

EDSA
-0.42%

Performance Overview

Return	EDSA	S&P 500 (^GSPC)
YTD	+39.88%	-6.68%
1-Year	-45.48%	+8.23%
3-Year	-86.68%	+28.49%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Edesa Biotech, Inc. (EDSA)

Edesa Biotech Announces Chief Financial Officer Transition

EDSA: Raises $15 Million to Advance EB06…

US Penny Stocks To Watch In February 2025

Edesa Biotech Announces $15.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

EDSA: IND Expected in 2025 for EB06 for the Treatment of Vitiligo…

Edesa Biotech And 2 Other Promising US Penny Stocks For Your Radar

Edesa Biotech Reports Fiscal Year 2024 Results

Edesa Biotech’s Founder Makes Strategic Investment in the Company

Edesa Biotech Announces Upcoming Conference Schedule

EDSA: EB05 Selected for BARDA-Funded Study in ARDS…

BARDA Selects Edesa Biotech's Drug for U.S. Funded Platform Trial in General ARDS

EDSA: Preparing IND for Phase 2 Trial of EB06 in Vitiligo

Edesa Biotech Reports Fiscal 2nd Quarter 2024 Results

Performance Overview